Locust Walk Insights

LOCUST WALK INSIGHTS

Maximizing Your JP Morgan Healthcare Conference

The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors, prospective partners, service providers, etc. and lay the groundwork for much of the...

We’re All Heart: Best in Show at TCT

It is that time of year again when the interventional cardiology and vascular communities reflect on the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting which took place in Denver and finished late last week.  We take pause to remember that TCT is one...

Finding the invisible, how to meet Family Offices

Besides calling the Ghostbusters, how does one catch a ghost?  That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...

Navigating the MedTech Fundraising Environment

For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained. New entrants...

Biotalk, Episode 5, Fred Chereau, LogicBio

In this episode of Biotalk, Josh Hamermesh, VP of Locust Walk, spoke to Fred Chereau, CEO of LogicBio, an innovative early-stage gene therapy company that recently completed a $50M financing. During the conversation, Josh and Fred discussed career paths, industry...

Q3 2017 Trends in Life Sciences Finance

Each quarter Locust Walk experts compile key statistics and trends on strategic transactions and financings. Our Q3 report uses the latest data to analyze current trends in the life science deal landscape. In this report you can find an overview and analysis of:...

Demystifying the Venture Capital Term Sheet

Raising capital for an emerging biotech company is rarely easy.  Tremendous time and effort goes into crafting the perfect story, determining the amount of capital you need to raise and what that money will be used for and reaching out to investors.  It can be a long...

When to use a structured deal process?

Though often overlooked or made by default, decisions about the structure and timing of a competitive deal process can have a significant impact on the ultimate value realized by the sell-side company. There are many important decisions that must be made in the...

What is the regulatory STATE of stem cells?

Stem cells seem to be everywhere.  We are constantly hearing discussions about the use of stem cells, regulatory issues for stem cells and the role for regenerative medicine.  The conversations bridge multiple therapeutic areas including orthopedics, cosmetics,...

What is the Point of Point of Care?

After stops and starts, successes and disappointments, point-of-care diagnostic testing (POCT) has finally come of age. From its humble beginnings in the 1990’s, POCT has become a $16 billion market, delivering value to patients, caregivers and investors. As a...

Key trends impacting Japan partnering

Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies. Doing deals is never easy, no matter the geography. However, it does seem that negotiating with Japanese companies...

Maximizing the Likelihood of Closing a Deal This Year

A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’.  Now it is early August, and we are deep in the summer slowdown.  Many of us are enjoying the last stints of our summer holidays before returning to...

Why is Family Office money so hard to find for life science companies?

As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know.  Raising money from family offices is hard. While there are several challenges to attracting...